Through selectively targeting #cancercells, antibody derivatives called antibody-drug conjugates (ADCs) can deliver small-molecule drugs to specific cells including cancer cells. #Cancercare is evolving with more research on ADCs.

Don’t let your software limit your ability to present data in meaningful ways. By exploring the future of reporting, we may develop intuitive, dynamic, and informative displays through smart reporting. Learn more about potential new tools.

ICYMI: We shared our #GenitourinaryCancer research at #ANZUP24.

The expanding knowledge of the tumor microenvironment (TME) has helped to improve our understanding of potential treatment targets. But how does it relate to pathways to cancer? There are several ways. ⬇️ #oncology

At Eisai, our global pipeline offers hope to families, patients, and caregivers. It’s a path to help find potential solutions for some of today’s most problematic diseases. Discover how it works.

Combination therapies, including antibody-drug conjugates (ADCs) and immune checkpoint inhibitors, are currently being studied. These combination strategies aim to transform “cold” tumors into “hot” ones, inviting the immune system back into the fight.

ICYMI: We were in Japan for the 60th Annual Meeting of the Japan Liver Cancer Association.

As we recognize World Breast Cancer Research Day this year, it is a reminder that although we’ve made great strides, there’s still so much work to be done. #clinicalresearch #bcsm

It’s important to understand the nuances of adverse event (AE) monitoring when it comes to tyrosine kinase inhibitors (TKIs). Clinicians, patients, and caregivers should all stay vigilant and report any issues in a timely manner. Here are some helpful tips.

Dual-drug ADCs tackle the challenge of intratumor heterogeneity in breast cancer by delivering two cytotoxic payloads, potentially providing new treatment strategies for patients with complex tumor profiles.

Discoveries in Wnt/β-catenin signaling offer new avenues for cancer therapy, highlighting the pathway's role in tumor growth and the challenge of targeting it without harming normal tissue regeneration.

Did you know? Worldwide, hepatocellular carcinoma is the sixth most frequently diagnosed cancer and the third most common cause of cancer mortality. Eisai is committed to continued oncology research for #HCC and other cancers.

Deregulation of complex signaling pathways may contribute to cancer, which has led to research and studies of targeted cancer therapies.

A multidisciplinary team (MDT) approach is essential when treating patients with Non-Small Cell Lung Cancer (NSCLC). Listen to Mark Socinski, MD, explain the importance of having centralized care for lung cancer patients. #lcsm

Creating therapeutics that target diseased cells requires understanding the differences in Wnt/β-catenin signaling between cancerous and normal cells and identifying unique disease-specific pathway regulators.

As part of our human health care mission, we have partnered with leading #advocacy groups to empower patients across a wide range of conditions. We are committed to providing patient resources and fostering supportive communities that enhance patient care and engagement. #cancer

Antibody-drug conjugates (ADCs) were historically used in hematological malignancies and have started to demonstrate potential impact on solid tumors.

See our presentations at #ESMO24 highlighting Eisai’s latest #cancer research

Though there have been many advancements in endometrial cancer (EC) research, #GCAM is a reminder that we must go further. We will be sharing our latest EC research at #ESMO24. ⬇️

Further research on renal cell carcinoma (#RCC) is ongoing. From September 13–17 we will be at the ESMO - Eur. Oncology congress to share our latest #RCC research. We hope to see you there. #ESMO24